In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers.

It is noteworthy that patients with mild TBI often report visual issues despite normal results of visual acuity measurements and fundus examinations.

Ahead of this year's Floretina meeting and International Congress on OCT Angiography, En Face OCT and Advances in OCT (ICOOR), David Hutton of Ophthalmology Times spoke with Charles Wykoff, MD, PhD. At FLORetina ICOOR, he presented on a number of topics, including diabetic retinopathy—the subject of his conversation with the Eye Care Network.

According to researchers, GPT-4o demonstrates potential in generating comprehensive differential glaucoma diagnoses but falls short in primary diagnostic accuracy, underscoring its role as a complementary tool rather than a standalone diagnostic solution.

The authors searched PubMed, Scopus, MEDLINE, ScienceDirect, and ClinicalTrials.gov, and selected studies based on reports with an association between RVO and heart attack risk.

This Week in Ophthalmology is a video series highlighting some of the top articles featured on the Ophthalmology Times website.

The company begins phase 1 trials of oral GAL-101, targeting amyloid beta aggregation. Promising safety and efficacy in ophthalmic models suggest potential for treating dry AMD, glaucoma, and neurodegenerative eye diseases.

In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers.

Retinal specialists conclude their discussion with key highlights from each patient case of retinal vascular disease and pearls the audience can apply in their practice.

In this final case, Sumit Sharma, MD, FASRS presents his case of neovascular AMD with a severe retinal pigment epithelial detachment who experienced a higher durability with a newer agent.

BostonSight’s pilot study, published in Clinical Ophthalmology, explores the use of PROSE scleral lenses as a drug delivery system for cyclosporine 0.05% in treating dry eye disease, showing promising symptom relief and tolerability.

The funding will primarily support advancement of Elate Ocular through its registration-enabling phase 3 clinical trials for dry eye disease.

Scott Hunter, who joined the company nearly 2 years ago, also had stints with Novartis, Shire, and Bausch + Lomb.

Researchers set out to determine the most important systemic risk factors associated with cataract development in patients with DM

According to the company, VVN461, a non-steroidal dual JAK1/TYK2 immunomodulator, achieved its primary endpoint, demonstrating statistical and clinical efficacy compared to vehicle in treating post-operative inflammation following cataract surgery.

Nerve cells in the retina were analyzed at the Vienna University of Technology using microelectrodes. According to researchers, the nerve cells demonstrated surprisingly stable behavior, which is good news for retina implants.